| 徐 炜,王安镅,王文龙,陈江锋,王际云.龟鹿二仙胶对晚期结直肠癌患者免疫细胞因子、TGF-β1/Smad信号通路的作用研究[J].,2024,(21):4090-4092 |
| 龟鹿二仙胶对晚期结直肠癌患者免疫细胞因子、TGF-β1/Smad信号通路的作用研究 |
| Study on the Effect of Guilu Erxian Glue on Immune Cytokines and TGF-β1/Smad Signaling Pathway in Patients with Advanced Colorectal Cancer |
| 投稿时间：2024-08-21 修订日期：2024-09-19 |
| DOI：10.13241/j.cnki.pmb.2024.21.016 |
| 中文关键词: 龟鹿二仙胶 晚期结直肠癌 免疫细胞因子 TGF-β1/Smad信号通路 |
| 英文关键词: Guilu Erxian Glue Advanced colorectal cancer Immune cytokines TGF-β1/Smad signaling pathway |
| 基金项目:浙江省中医药科学研究基金项目（2022ZB287） |
|
| 摘要点击次数: 118 |
| 全文下载次数: 32 |
| 中文摘要: |
| 摘要 目的：探讨龟鹿二仙胶对晚期结直肠癌患者免疫细胞因子、转化生长因子β1（TGF-β1）/果蝇母本抗生存因子蛋白（Smad）信号通路的作用。方法：根据双色球法将82例晚期结直肠癌患者分为对照组和观察组，各为41例。对照组接受FOLFIRI方案化疗，观察组接受龟鹿二仙胶、FOLFIRI方案化疗。比较两组治疗前后中医证候积分、免疫细胞因子指标、血清TGF-β1/Smad信号通路指标，同时观察两组不良反应发生情况。结果：与对照组治疗后相比，观察组中医证候（乏力明显、食欲降低、腰膝酸软、气短、大便溏薄）积分、CD8+和血清TGF-β1、Smad3水平更低，血清Smad7水平、CD4+、自然杀伤（NK）细胞、CD4+/CD8+更高（P＜0.05）。对照组（41.46%）、观察组（29.27%）不良反应发生率对比未见差异（P＞0.05）。结论：龟鹿二仙胶可能通过调节免疫细胞因子、抑制TGF-β1/Smad信号通路从而辅助改善晚期结直肠癌患者的临床症状。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Guilu Erxian Glue on immune cytokines and transforming growth factor-β1 (TGF-β1)/Drosophila mothers against decapentaplegic protein (Smad) signaling pathway in patients with advanced colorectal cancer. Methods: 82 patients with advanced colorectal cancer were divided into control group and observation group according to the two-color ball method, 41 cases each. Control group received FOLFIRI regimen chemotherapy, and observation group received Guilu Erxian Glue and FOLFIRI regimen chemotherapy. The traditional Chinese medicine syndrome scores, immune cytokines and serum TGF-β1/Smad signaling pathway indexes in two groups before and after treatment were compared, and the incidence of adverse reactions in two groups was observed. Results: Compared with control group after treatment, the scores of traditional Chinese medicine syndromes (obvious fatigue, decreased appetite, soreness and weakness of waist and knees, shortness of breath, thin stool), CD8+ and serum TGF-β1, Smad3 levels in observation group were lower, and serum Smad7 levels, CD4+, natural killer (NK) cells, CD4+/CD8+ were higher (P<0.05). There was no difference in the incidence of adverse reactions between control group (41.46%) and observation group (29.27%) (P>0.05). Conclusion: Guilu Erxian Glue may assist in improving the clinical symptoms of patients with advanced colorectal cancer by regulating immune cytokines and inhibiting TGF-β1/Smad signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
